Antiphospholipid antibody syndrome: Immunologic and clinical aspects

Seminars in Arthritis and Rheumatism

Volumn 20, Issue 2, 1990, Pages 81-96

  Sammaritano, Lisa R ^a   Gharavi, Azzudin E ^b   Lockshin, Michael D ^c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

anticardiolipin antibody; Antiphospholipid antibody; lupus anticoagulant; SLE

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; HEPARIN; LUPUS ANTICOAGULANT; PREDNISONE; WARFARIN;

ABORTION; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; DIAGNOSIS; ETIOLOGY; FAMILIAL DISEASE; HUMAN; LIVEDO RETICULARIS; MOUSE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS;

ANTIBODIES; FETAL DEATH; HEART DISEASES; HEMATOLOGIC DISEASES; HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; NERVOUS SYSTEM DISEASES; PHOSPHOLIPIDS; SKIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SYNDROME; THROMBOSIS; VASCULAR DISEASES;

EID: 0025103907     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-0172(90)90021-7     Document Type: Article

References (208)

1. Antiphospholipid antibodies and disease
2. Antiphospholipid antibodies—Autoantibodies with a difference
3. Lupus anticoagulant—Related conditions
4. Antiphospholipid antibodies Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus and in non SLE disorders Prevalence and clinical significance
5. Antiphospholipid antibodies
6. The anticardiolipin syndrome
7. Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin antibody test
8. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
9. Primary antiphospholipid syndrome Features of patients with raised anticardiolipin antibodies and no other disorder
10. Primary antiphospholipid syndrome
11. The “primary” antiphospholipid syndrome: Major clinical and eroiogical features
12. The diagnostic reaction for syphilis (Ger)
13. Connective tissue disease and the chronic biologic false-positive test for syphilis (BFP reaction)
14. The 1982 revised criteria for the classification of systemic lupus erythematosus
15. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus
16. A clinical study of the lupus anticoagulant
17. The lupus anticoagulant
18. Thrombosis in patients with the lupus anticoagulant
19. Thrombosis in systemic lupus erythematosus: Striking association with the presence of circulating lupus anticoagulant
20. Thromboembolism in patients with the “lupus” type circulating anticoagulant
21. Monoclonal Immunoglobulin M lamda coagulation inhibitor with phospholipid specificity
22. Immunological specificity and mechanism of action of IgG lupus anticoagulants
23. Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulants
24. Antiphospholipid antibodies in syphilis and a thrombotic subset of SLE: Distinct profiles of epitope specificity
25. Antiphospholipid antibodies and biological false positive seroiogical test for syphilis in patients with systemic lupus erythematosu
26. Evaluation of the cross reaction between antiDNA and anticardiolipin antibodies in SLE and experimental animais
27. Binding specificity of lupus anticoagulants and anticardiolipin antibodies
28. Hazards of lupus pregnancy
29. The relationship between lupus anticoagulants and antibodies to phospholipids
30. Simultaneous lupus anticoagulant and anticardiolipin assays and clinical detection of antiphospholipids
31. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population
32. Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin time
33. A sensitive test demonstrating lupus anticoagulant and its behavioral patterns
34. Similar mechanism of various lupus anticoagulants
35. Comparison of two simple tests for the lupus anticoagulant
36. Detection and quantitative evaluation of lupus circulating anticoagulant activity
37. Comparison of laboratory tests used for identification of the lupus anticoagulant
38. Relative sensitivity of different tests in the detection of low titer lupus anticoagulants
39. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column
40. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics
41. Antiprothrombin antibodies and the lupus anticoagulant
42. Affinity purified anticardiolipin and anti-DNA antibodies
43. Anticoagulant activity of anticardiolipin antibodies
44. Antiphospholipid antibody and placental anticoagulant protein
45. Evaluation of the anticardiolipin antibody test: Report of an international workshop
46. Coagulation screen is more specific than the anticardiolipin ELISA in defining a thrombotic subset of lupus patients
47. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody
48. Comparison of antibody to cardiolipin and aPTT as predictors of fetal death in pregnant patients with SLE
49. Anticardiolipin antibodies: Isotype distribution and phospholipid specificity
50. Binding affinity of serum immunoglobulin G to cardiolipin and other phospholipids in patients with systemic lupus erythematosus and syphilis
51. Characteristics of IgG antiphospholipid antibodies in patientswith SLE and syphilis
52. IgG subclass and light chain distribution of anticardiolipin and anti-DNA antibodies in systemic lupus erythematosus
53. Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders
54. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody
55. Subclass restriction and polyclonality of the systemic lupus erythematosus marker anti-Sm
56. The subclass of antinuclear and antinucleic acid antibodies
57. IgG subclasses of autoantibodies in systemic lupus erythematosus, Sjogren's syndrome, and drug-induced autoimmunity
58. Immunoblot analysis of IgG subclasses of multiple lupus antibodies
59. IgG subclass distribution of anticardiolipin antibody in patients with systemic lupus erythematosus
60. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response
61. IgG subclass of anti-tetanus toxoid antibodies in adult and newborn normal subjects and in patients with systemic lupus erythematosus, Sjogren's syndrome, and drug induced autoimmunity
62. Immunoglobulins I: Structure and function
63. Polyspecificity of monoclonal lupus autoantibodies produced by human—Human hybridomas
64. The lupus anticoagulant: A disease marker in antinuclear antibody negative lupus that is cross-reactive with autoantibodies to double-stranded DNA
65. Idiotypic cross reactions of monoclonal human lupus autoantibodies
66. Is anticardiolipin activity a cross reaction of antiDNA or a separate entity?
67. Measurements of the true affinity constant in solution of antigen—antibody complexes by enzyme—linked immunosorbment assay
68. Crossreactivity of antiphospholipid antibodies
69. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis
70. The specificity of anticardiolipin antibodies from syphilis patients and from patients with systemic lupus erythematosus
71. Fatty acid chain is a critical epitope for antiphospholipid antibody
72. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems
73. IgC anticardiolipin antibodies in murine lupus
74. Characteristics of high titer IgG antiphospholipid antibody (aPL) in systemic lupus erythematosus patients with and without fetal death
75. The regulation of natural anticoagulant pathways
76. Regulation of plasminogen activators and their inhibitors in rheumatic diseases: New understanding and the potential for new directions
77. Antiendothelial cell antibodies
78. Presence of complement-fixing antiendothelial cell antibodies in systemic lupus erythematosus
79. Measurement and characterization of circulating anti-endothelial cell IgG in connective tissue diseases
80. Relationship between anticardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus
81. IgG binding to endothelial cells in systemic lupus erythematosus
82. Antibody and immune complexes induce tissue factor production by human endothelial cells
83. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: Detection of immunoglobulin interfering with prostacyclin formation
84. “Lupus” anticoagulant and thrombosis—possible role of inhibition of prostacyclin formation
85. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis
86. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity
87. The lupus anticoagulant does not inhibit the release of prostacyclin from human endothelial cells
88. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells—Inhibition of thrombomodulin dependent protein C activation
89. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant
90. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity—A mechanism for thrombosis
91. Human thrombomodulin is inhibited by IgG from 2 patients with non-specific anticoagulants
92. Predisposing factors to thrombosis in systemic lupus erythematosus: Possible relation to endothelial cell damage
93. Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus
94. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis
95. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant
96. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes
97. Lupus anticoagulant and antiplatelet properties of human hybridoma antibodies
98. Anticardiolipin antibodies in infectious mononucleosis react with the membrane of activated lymphocytes
99. Interaction between lupus anticoagulant and platelets
100. Protein S deficiency in patients with the lupus anticoagulant
101. Protein S and anticardiolipin antibodies in patients with lupus anticoagulant with or without thrombosis
102. Reduced free protein S in patients with the lupus anticoagulant
103. Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: Report of 2 cases
104. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis
105. Antithrombin III in systemic lupus erythematosus
106. Prekallikrein inhibition associated with the lupus anticoagulant: A mechanism of thrombosis
107. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord
108. Human placental anticoagulant protein: Isolation and characterization
109. Purification and characterization of a novel protein from bovine aorta that inhibits coagulation
110. Antiphospholipid antibodies are directed against a complex antigen which includes a lipid-binding glycoprotein
111. Clinical significance of a single test for anticardiolipin antibodies
112. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus
113. Lupus anticoagulant: Revival of an old phenomenon
114. IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes
115. Recurrent ischaemic attacks in 2 young adults with lupus anticoagulant
116. Cerebral infarction associated with lupus anticoagulants—preliminary report
117. Cerebral infarction in systemic lupus: Association with anticardiolipin antibodies
118. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid antibody syndrome
119. Obstetric complications associated with the lupus anticoagulant
120. Lupus anticoagulant and pregnancy
121. Immunologic disease and fetal death
122. Thrombocytopenia in SLE and related autoimmune disorders: Association with anticardiolipin antibody
123. Antiphospholipid antibodies in systemic lupus erythematosus: Evidence of an association with positive Coombs' and hypocomplementemia
124. Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies
125. Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus
126. Thrombotic skin disease as a marker of the anticardiolipin syndrome: Livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity
127. IgM-containing immune complexes and antiphospholipid antibodies in patients with Sneddon's syndrome
128. The spectrum of livedo reticularis and anticardiolipin antibodies
129. Association of lupus anticoagulant and severe valvular heart disease in systemic lupus erythematosus
130. Recurrent cerebral ischemia and mitral valve vegetation in a patient with antiphospholipid antibodies
131. The expanding spectrum of Libman Sacks endocarditis: The role of antiphospholipid antibodies
132. Diagnostic and therapeutic problems in 2 patients with antiphospholipid antibodies, heart valve lesions, and transient ischaemic attacks
133. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome
134. Antiphospholipid antibodies and chorea
135. Chorea in systemic lupus erythematosus and “lupus-like” disease: Association with antiphospholipid antibodies
136. Lupus anticoagulant, antiphospholipid antibodies, and migraine
137. Neurological disease associated with antiphospholipid antibodies
138. Transverse myelitis: A manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies
139. Anticardiolipin response in acute infections
140. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome
141. Lupus anticoagulant and AIDS
142. Anticardiolipin antibodies associated with HTLV-III infection
143. Anticardiolipin antibodies in acquired immunodeficiency syndrome
144. Anticardiolipin antibodies in Lyme disease
145. Immunologic and coagulation disorders in chlorpromazine-treated patients
146. Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities
147. Anticardiolipin antibodies in patients with systemic lupus erythematosus
148. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus
149. Antiphospholipid antibodies in the connective tissue diseases: Their relationship to the antiphospholipid syndrome and forme fruste disease
150. Anticardiolipin antibodies in patients with rheumatic diseases
151. Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients
152. Cardiolipin antibodies and null alleles of C4 in black Americans with systemic lupus erythematosus
153. High incidence of anticardiolipin antibodies in relatives of patients with systemic lupus erythematosus
154. Antinuclear autoantibodies in sera of healthy pregnant women and their offspring
155. Relationship between antiphospholipid antibodies and recurrent fetal loss in patients with systemic lupus erythematosus and apparently healthy women
156. Habitual fetal loss may indicate autoimmune disease
157. Circulating anticoagulant in patients seropositive for human immunodeficiency virus
158. Anticardiolipin antibodies in systemic sclerosis
159. Anticardiolipin antibodies: Occurrence in Behcet's syndrome
160. Familial association of lupus anticoagulant
161. Familial lupus anticoagulants
162. Familial occurrence of the antiphospholipid syndrome
163. HLA-DR antigens and anticardiolipin antibodies in Northern Italian systemic lupus erythematosus patients
164. Gangrene developing after minor surgery in a patient with undiagnosed systemic lupus erythematosus and lupus anticoagulant
165. Large vessel occlusion and gangrene in systemic lupus erythematosus and “lupus-like” disease. A report of six cases
166. Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the “primary” antiphospholipid syndrome
167. Visual symptoms associated with the presence of a lupus anticoagulant
168. Lupus retinopathy: Patterns, associations, prognosis
169. Amaurosis fugax associated with antiphospholipid antibodies
170. Central retinal artery occlusion in Sneddon's disease associated with antiphospholipid antibodies
171. Occlusive retinal vascular disease in systemic lupus erythematosus
172. Renal vein thrombosis in systemic lupus erythematosus: Association with the “lupus anticoagulant.”
173. Budd Chiari syndrome, visceral arterial occlusions, recurrent fetal loss and the “lupus anticoagulant” in systemic lupus erythematosus
174. Lupus anticoagulant and portal hypertension
175. Multiple venous and arterial thromboses associated with the lupus anticoagulant and antibodies to cardiolipin in the absence of SLE
176. Antiphospholipid antibody syndrome with right atrial thrombosis mimicking an atrial myxoma
177. Acute adrenal insufficiency as a manifestation of the anticardiolipin syndrome?
178. Acute adrenal insufficiency with the antiphospholipid syndrome
179. Antibodies to cardiolipin and vascular complications in women taking oral contraceptives
180. Complications of oral contraceptives and antiphospholipid antibodies: Reply to the letter by Bruneau et al
181. A maternal death due to thrombotic disease associated with anticardiolipin antibody
182. Clinical and immunologic features of livedo reticularis in lupus: A case-control study
183. Sterility and fertility rates, fetal wastage and maternal morbidity in systemic lupus erythematosus
184. Systemic lupus erythematosus in pregnancy: UCLA conference
185. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus
186. Antibodies to phospholipids and nuclear antigens in patients with repeated abortions
187. Anticardiolipin antibodies and complement in ninety-nine women with habitual abortion
188. Antiphospholipid antibodies in early repeated abortions: A case-controlled study
189. Pregnancy in patients with rheumatic diseases: Antiphospholipid antibody syndromes
190. Significance of false positive syphilis reactions and anticardiolipin antibodies in a nationwide series of pregnant women
191. Placental lesions in maternal autoimmune diseases
192. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant
193. Lupus pregnancy A prospective study of placental changes
194. Fetal loss treatment in patients with antiphospholipid antibodies
195. Second-trimester fetal monitoring and preterm delivery in pregnancies with systemic lupus erythematosus and/or circulating anticoagulant
196. Anticardiolipin antibodies in autoimmune thrombocytopenic purpura
197. Hemocytopenia in systemic lupus erythematosus. Relationship to antiphospholipid antibodies
198. Coronary artery vasculitis and myocardial infarction associated with antiphospholipid antibodies in a pregnant woman
199. Cerebrovascular accident and myocardial infarction associated with anticardiolipin antibodies in a young women with systemic lupus erythematosus
200. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events
201. Coronary artery bypass graft failure—an autoimmune phenomenon
202. Chorea gravidarum associated with circulating lupus anticoagulant: Successful outcome of pregnancy with prednisone and aspirin therapy
203. Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal
204. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome
205. Fetal survival after prednisone suppression of maternal lupus anticoagulant
206. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies
207. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization
208. Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy